Records 1 - 3
| Association of pharmacokinetics and pharmacogenomics with safety and efficacy of gefitinib in patients with EGFR mutation positive advanced non-small cell lung cancer.
Lung cancer (Amsterdam, Netherlands) 2016 Mar 93 69-76.
Hirose Takashi, Fujita Ken-Ichi, Kusumoto Sojiro, Oki Yasunari, Murata Yasunori, Sugiyama Tomohide, Ishida Hiroo, Shirai Takao, Nakashima Masanao, Yamaoka Toshimitsu, Okuda Kentaro, Ohmori Tohru, Sasaki Yasutsu
| Relationship Among Gefitinib Exposure, Polymorphisms of Its Metabolizing Enzymes and Transporters, and Side Effects in Japanese Patients With Non-Small-Cell Lung Cancer.
Clinical lung cancer 2015 Jul 16 (4): 274-81.
Kobayashi Hiroyuki, Sato Kazuhiro, Niioka Takenori, Miura Hajime, Ito Hiroshi, Miura Masato
| Reduced CYP2D6 function is associated with gefitinib-induced rash in patients with non-small cell lung cancer.
BMC cancer 2012 Dec 12 (1): 1.
Suzumura T, Kimura T, Kudoh S, Umekawa K, Nagata M, Matsuura K, Tanaka H, Mitsuoka S, Yoshimura N, Kira Y, Nakai T, Hirata K